Aydemir A - Search Results

1

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.

Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G; JANUS study investigators. Barratt J, et al. Among authors: aydemir a. Kidney Int Rep. 2022 May 26;7(8):1831-1841. doi: 10.1016/j.ekir.2022.05.017. eCollection 2022 Aug. Kidney Int Rep. 2022. PMID: 35967104 Free PMC article.

2

A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis.

Dahlberg LE, Aydemir A, Muurahainen N, Gühring H, Fredberg Edebo H, Krarup-Jensen N, Ladel CH, Jurvelin JS. Dahlberg LE, et al. Among authors: aydemir a. Clin Exp Rheumatol. 2016 May-Jun;34(3):445-50. Epub 2016 Mar 23. Clin Exp Rheumatol. 2016. PMID: 27050139 Clinical Trial.

3

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.

Isenberg DA, Kao AH, Aydemir A, Merrill JT. Isenberg DA, et al. Among authors: aydemir a. Front Immunol. 2020 Nov 11;11:592639. doi: 10.3389/fimmu.2020.592639. eCollection 2020. Front Immunol. 2020. PMID: 33262771 Free PMC article. No abstract available.

4

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.

Wallace DJ, Isenberg DA, Morand EF, Vazquez-Mateo C, Kao AH, Aydemir A, Pudota K, Ona V, Aranow C, Merrill JT. Wallace DJ, et al. Among authors: aydemir a. Rheumatology (Oxford). 2021 Nov 3;60(11):5379-5389. doi: 10.1093/rheumatology/keab115. Rheumatology (Oxford). 2021. PMID: 33547784 Clinical Trial.

5

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.

Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, Townsend R, Mateo CV, Studham M, Guenther O, Kao A, Gastonguay M, Girard P, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: aydemir a. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):180-195. doi: 10.1002/psp4.12888. Epub 2022 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36350330 Free PMC article.

6

Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies.

Studham M, Vazquez-Mateo C, Samy E, Haselmayer P, Aydemir A, Rolfe PA, Merrill JT, Morand EF, DeMartino J, Kao A, Townsend R. Studham M, et al. Among authors: aydemir a. ACR Open Rheumatol. 2023 Oct;5(10):536-546. doi: 10.1002/acr2.11594. Epub 2023 Sep 14. ACR Open Rheumatol. 2023. PMID: 37710418 Free PMC article.

7

Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.

Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, Reinstrup Bihlet A, Byrjalsen I, Ragnar Andersen J, Eckstein F. Hochberg MC, et al. Among authors: aydemir a. JAMA. 2019 Oct 8;322(14):1360-1370. doi: 10.1001/jama.2019.14735. JAMA. 2019. PMID: 31593273 Free PMC article. Clinical Trial.

8

Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years.

Roemer FW, Kraines J, Aydemir A, Wax S, Hochberg MC, Crema MD, Guermazi A. Roemer FW, et al. Among authors: aydemir a. Osteoarthritis Cartilage. 2020 Sep;28(9):1229-1234. doi: 10.1016/j.joca.2020.05.015. Epub 2020 Jun 30. Osteoarthritis Cartilage. 2020. PMID: 32619609 Free article. Clinical Trial.

9

The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.

Butzkueven H, Moore N, Aydemir A, Sõnajalg J, Bezemer I, Korhonen P, Sabidó M; CLARION Study Group. Butzkueven H, et al. Among authors: aydemir a. Curr Med Res Opin. 2022 Jul;38(7):1167-1176. doi: 10.1080/03007995.2022.2059977. Epub 2022 Apr 28. Curr Med Res Opin. 2022. PMID: 35357268

10

Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging.

Eckstein F, Wirth W, Guermazi A, Maschek S, Aydemir A. Eckstein F, et al. Among authors: aydemir a. Arthritis Rheumatol. 2015 Nov;67(11):2916-22. doi: 10.1002/art.39265. Arthritis Rheumatol. 2015. PMID: 26138203 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page